348 related articles for article (PubMed ID: 26538316)
1. Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease.
Kalimutho M; Parsons K; Mittal D; López JA; Srihari S; Khanna KK
Trends Pharmacol Sci; 2015 Dec; 36(12):822-846. PubMed ID: 26538316
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
Yam C; Mani SA; Moulder SL
Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413
[TBL] [Abstract][Full Text] [Related]
3. Triple Negative Breast Cancer: A Tale of Two Decades.
Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
[TBL] [Abstract][Full Text] [Related]
4. The evolving management of metastatic triple negative breast cancer.
Malhotra MK; Emens LA
Semin Oncol; 2020 Aug; 47(4):229-237. PubMed ID: 32563561
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
6. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
Bianchini G; Balko JM; Mayer IA; Sanders ME; Gianni L
Nat Rev Clin Oncol; 2016 Nov; 13(11):674-690. PubMed ID: 27184417
[TBL] [Abstract][Full Text] [Related]
7. Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies.
Lee A; Djamgoz MBA
Cancer Treat Rev; 2018 Jan; 62():110-122. PubMed ID: 29202431
[TBL] [Abstract][Full Text] [Related]
8. The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC).
Narrandes S; Huang S; Murphy L; Xu W
BMC Cancer; 2018 Jan; 18(1):22. PubMed ID: 29301506
[TBL] [Abstract][Full Text] [Related]
9. Triple-negative breast cancer: molecular subtypes and targeted therapy.
Hirshfield KM; Ganesan S
Curr Opin Obstet Gynecol; 2014 Feb; 26(1):34-40. PubMed ID: 24346128
[TBL] [Abstract][Full Text] [Related]
10. Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification.
Guestini F; McNamara KM; Ishida T; Sasano H
Expert Opin Ther Targets; 2016 Jun; 20(6):705-20. PubMed ID: 26607563
[TBL] [Abstract][Full Text] [Related]
11. Recent therapeutic trends and promising targets in triple negative breast cancer.
Hwang SY; Park S; Kwon Y
Pharmacol Ther; 2019 Jul; 199():30-57. PubMed ID: 30825473
[TBL] [Abstract][Full Text] [Related]
12. Triple-negative breast cancer: advancements in characterization and treatment approach.
Hurvitz S; Mead M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC).
Wein L; Loi S
Breast; 2017 Aug; 34 Suppl 1():S27-S30. PubMed ID: 28668293
[TBL] [Abstract][Full Text] [Related]
14. Targeting triple negative breast cancer with histone deacetylase inhibitors.
Fedele P; Orlando L; Cinieri S
Expert Opin Investig Drugs; 2017 Nov; 26(11):1199-1206. PubMed ID: 28952409
[TBL] [Abstract][Full Text] [Related]
15. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
16. Role of the androgen receptor in triple-negative breast cancer.
Rampurwala M; Wisinski KB; O'Regan R
Clin Adv Hematol Oncol; 2016 Mar; 14(3):186-93. PubMed ID: 27058032
[TBL] [Abstract][Full Text] [Related]
17. Subtyping of triple-negative breast cancer: implications for therapy.
Abramson VG; Lehmann BD; Ballinger TJ; Pietenpol JA
Cancer; 2015 Jan; 121(1):8-16. PubMed ID: 25043972
[TBL] [Abstract][Full Text] [Related]
18. Triple-negative breast cancer and the potential for targeted therapy.
Jhan JR; Andrechek ER
Pharmacogenomics; 2017 Nov; 18(17):1595-1609. PubMed ID: 29095114
[TBL] [Abstract][Full Text] [Related]
19. PIM1: a promising target in patients with triple-negative breast cancer.
Zhao W; Qiu R; Li P; Yang J
Med Oncol; 2017 Aug; 34(8):142. PubMed ID: 28721678
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer.
Gregório AC; Lacerda M; Figueiredo P; Simões S; Dias S; Moreira JN
Pathol Oncol Res; 2018 Oct; 24(4):701-716. PubMed ID: 28913723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]